An advantage of plasmid-based vector systems for gene therapy over virus-based is their low immunogenicity. The Sleeping Beauty (SB) transposon system, which has the ability to integrate genes into human chromosomes, is a candidate for gene therapy of mucopolysaccharidoses (MPS), genetic disorders of lysosomal metabolism that require sustained expression of the therapeutic transgene. However, our attempts to achieve long-term expression of human alpha -L- iduronidase (hIDUA) or beta-glucuronidase (hGUSB) without immune suppression resulted in almost complete loss of transgene expression and maintenance by 4 weeks postinjection in both MPS and wild type (WT ) mice. In cyclophosphamide-immune-suppressed MPS I mice, the initial supranormal, 1-day plasma activity levels dropped approximately 150-fold by 2 weeks, but then persisted at detectable levels in some mice (see abstract by Aronovich et al). This suggested that cells that expressed the human therapeutic gene induced immune response and were cleared from the liver of some treated mice.The purpose of this study was to analyze contribution of cell- mediated immune response to the clearance of liver cells expressing foreign transgenes. We used high-pressure (hydrodynamic), tail-vein injection to deliver the transposon vectors pT2/mCAGGS-(hIDUA/hGUSB/Luc)//Ub-SB11 to the liver of WT C57Bl/6 mice. The efficiency of injection was evaluated 24 hr postinjection for transgene expression by either enzyme assay for IDUA or GUSB in plasma or in vivo imaging of luciferase (Luc). Mice were euthanized at 7, 10, 14, 17, 21 and 28 days and livers were extracted. Adjacent 5-μm sections from each liver were analyzed for transgene expression (histochemical staining for GUSB), for the presence of cellular infiltrates (H&E staining), and for the presence of CD4+ and CD8+ lymphocytes (immunohistochemical staining). In addition, the maintenance of the hIDUA, hGUSB and Luc transgene, as well as persistence of the transposon plasmid, were determined by PCR. Our results show the temporal relationship between expression of the therapeutic transgene and induction of immune response in the livers of transgene-treated mice.P.B. Hackett and R.S. McIvor have financial interest in Discovery Genomics, Inc. An advantage of plasmid-based vector systems for gene therapy over virus-based is their low immunogenicity. The Sleeping Beauty (SB) transposon system, which has the ability to integrate genes into human chromosomes, is a candidate for gene therapy of mucopolysaccharidoses (MPS), genetic disorders of lysosomal metabolism that require sustained expression of the therapeutic transgene. However, our attempts to achieve long-term expression of human alpha -L- iduronidase (hIDUA) or beta-glucuronidase (hGUSB) without immune suppression resulted in almost complete loss of transgene expression and maintenance by 4 weeks postinjection in both MPS and wild type (WT ) mice. In cyclophosphamide-immune-suppressed MPS I mice, the initial supranormal, 1-day plasma activity levels dropped approximately 150-fold by 2 weeks, but then persisted at detectable levels in some mice (see abstract by Aronovich et al). This suggested that cells that expressed the human therapeutic gene induced immune response and were cleared from the liver of some treated mice. The purpose of this study was to analyze contribution of cell- mediated immune response to the clearance of liver cells expressing foreign transgenes. We used high-pressure (hydrodynamic), tail-vein injection to deliver the transposon vectors pT2/mCAGGS-(hIDUA/hGUSB/Luc)//Ub-SB11 to the liver of WT C57Bl/6 mice. The efficiency of injection was evaluated 24 hr postinjection for transgene expression by either enzyme assay for IDUA or GUSB in plasma or in vivo imaging of luciferase (Luc). Mice were euthanized at 7, 10, 14, 17, 21 and 28 days and livers were extracted. Adjacent 5-μm sections from each liver were analyzed for transgene expression (histochemical staining for GUSB), for the presence of cellular infiltrates (H&E staining), and for the presence of CD4+ and CD8+ lymphocytes (immunohistochemical staining). In addition, the maintenance of the hIDUA, hGUSB and Luc transgene, as well as persistence of the transposon plasmid, were determined by PCR. Our results show the temporal relationship between expression of the therapeutic transgene and induction of immune response in the livers of transgene-treated mice. P.B. Hackett and R.S. McIvor have financial interest in Discovery Genomics, Inc.
Read full abstract